SS-31 Research Material — Product Overview
SS-31 is a synthetic tetrapeptide investigated in mitochondrial and membrane-associated laboratory research.
The compound is also identified in scientific and regulatory literature as elamipretide, and earlier research literature may refer to it as MTP-131 or Bendavia.
SS-31 contains four amino-acid-related residues, including a non-standard dimethyltyrosine residue. Its molecular structure has been investigated in research involving interactions with cardiolipin, a phospholipid associated with the inner mitochondrial membrane.
Nexigen SS-31 10 mg is supplied exclusively as a laboratory research material for analytical and scientific investigation.
The information on this page is provided to identify the material, summarize relevant research context and provide access to available lot-specific analytical documentation.
This material is intended strictly for laboratory research and is not intended for human or veterinary use or consumption.
SS-31 10 mg — Research Specifications
| Specification | Information |
|---|---|
| Compound | SS-31 |
| Scientific Name / Synonym | Elamipretide |
| Additional Research Synonym | MTP-131 |
| Quantity | 10 mg |
| Compound Type | Synthetic tetrapeptide |
| CAS Number | 736992-21-5 |
| Molecular Formula | C32H49N9O5 |
| Molecular Weight | Approximately 639.8 g/mol |
| Sequence | D-Arg-2,6-dimethylTyr-Lys-Phe-NH2 |
| Form | Refer to current product documentation |
| Brand | Nexigen Peptides |
| Lot / Batch | Refer to current product documentation |
| Analytical Method | Refer to current batch documentation |
| Reported Result | Refer to current batch documentation |
| Laboratory Handling | Protocol dependent; refer to validated laboratory procedures and applicable lot documentation |
| Intended Use | Laboratory research only |
SS-31/elamipretide is identified as a synthetic tetrapeptide with CAS 736992-21-5, molecular formula C32H49N9O5, molecular weight of approximately 639.8 g/mol, and a sequence corresponding to D-Arg-2,6-dimethylTyr-Lys-Phe-NH2.
What Is SS-31?
SS-31 is a synthetic tetrapeptide also known as elamipretide and MTP-131 that has been investigated in research involving mitochondrial membranes and cardiolipin-associated molecular interactions.
The peptide belongs to the class historically described as Szeto-Schiller peptides, or SS peptides.
Research has examined the interaction of SS-31 with cardiolipin, a phospholipid concentrated within the inner mitochondrial membrane.
Cardiolipin participates in the structural organization of mitochondrial membranes and provides an important experimental target for research into mitochondrial membrane chemistry and bioenergetic systems.
Earlier scientific literature investigated SS-31 as a cardiolipin-interacting peptide and examined how those molecular interactions affected mitochondrial structure and biochemical processes under experimental conditions.
Nexigen supplies SS-31 exclusively as a laboratory research material.
SS-31, Elamipretide and MTP-131: Are They the Same Compound?
Scientific literature has used several names for SS-31.
SS-31
SS-31 is the name commonly associated with the peptide’s early research history and the Szeto-Schiller peptide class.
MTP-131
MTP-131 is another research-development identifier that appears in scientific publications.
Elamipretide
Elamipretide is the recognized generic name associated with the compound. Elamipretide, MTP-131 and Bendavia are among the names associated with the same underlying peptide identity in scientific literature.
These terms therefore refer to the same underlying active peptide identity when used appropriately in the scientific literature.
Researchers should nevertheless verify the exact chemical form, salt form and analytical documentation associated with the specific research material they are evaluating.
Current Scientific and Regulatory Context
Elamipretide is no longer solely an investigational compound.
In September 2025, the U.S. Food and Drug Administration granted accelerated approval to Forzinity (elamipretide) for a specific indication involving patients with Barth syndrome weighing at least 30 kg.
That approval applies to the FDA-approved pharmaceutical product and its labeled indication.
The Nexigen material described on this page is presented as a laboratory research material and should not be interpreted as the approved pharmaceutical product or as a substitute for an FDA-approved medicine.
Nexigen does not provide therapeutic, clinical, dosing or administration guidance.
SS-31 Research Context
SS-31 has been investigated extensively in experimental research involving mitochondrial membranes, cardiolipin and mitochondrial bioenergetics.
A central area of investigation concerns interactions between SS-31 and cardiolipin.
Cardiolipin is a specialized phospholipid associated with the inner mitochondrial membrane. Research has examined how cardiolipin organization and interactions with proteins contribute to mitochondrial membrane structure and biochemical function.
Studies involving SS-31 have explored these molecular relationships in experimental systems.
Cardiolipin-Associated Research
Earlier research characterized SS-31 as a peptide capable of associating with cardiolipin through electrostatic and hydrophobic interactions.
Mitochondrial Membrane Research
Laboratory and preclinical studies have used SS-31 as a tool for investigating mitochondrial membrane organization and associated biochemical processes.
Bioenergetic Research
SS-31 has also appeared in experimental literature involving mitochondrial bioenergetics and cellular-energy systems.
Current Scientific Literature
Research has examined the structure, molecular interactions and experimental history of elamipretide/SS-31 across multiple mitochondrial research systems.
Research findings depend upon the experimental model, methodology, sample preparation and conditions used.
Scientific literature described on this page is presented only to identify areas of investigation and should not be interpreted as establishing that Nexigen SS-31 provides a particular human or veterinary outcome.
Experimental Research Characteristics
Several features make SS-31 an important molecular tool in mitochondrial research.
Tetrapeptide Structure
SS-31 is composed of four amino-acid-related residues, including a non-standard dimethyltyrosine residue.
Its relatively compact structure differs from longer conventional peptides.
Cardiolipin Interaction
A major focus of SS-31 research concerns its interaction with cardiolipin.
That interaction has made the compound useful in experimental systems designed to investigate mitochondrial membrane organization and associated molecular processes.
Mitochondrial Localization
Scientific literature describes elamipretide as associating with the inner mitochondrial membrane and cardiolipin-containing environments.
Experimental Context Matters
Observed behavior can depend significantly upon:
- Research model
- Peptide concentration
- Membrane composition
- Cellular system
- Assay methodology
- Sample preparation
- Analytical technique
- Exposure conditions
Researchers should therefore consult original scientific publications when selecting methods or interpreting SS-31 experimental results.
Evaluating SS-31 as a Research Peptide
Researchers sourcing SS-31 or other research peptides should evaluate more than the material name and nominal quantity.
Correct Compound Identity
Compound name, CAS number, sequence and molecular information should all describe the same research material.
Correct chemical identification is particularly important because an incorrect identifier can associate a research material with an entirely different compound.
Lot Traceability
Researchers should be able to identify which lot corresponds to the available analytical documentation.
Analytical Methodology
The testing method used for a particular batch should be identified whenever possible.
Batch-Specific Results
A result generated for one lot should not automatically be assumed to characterize another.
Chemical Form
Researchers should determine whether documentation applies to the free peptide, a salt or another defined material form.
Documentation Accessibility
Relevant Certificates of Analysis and analytical reports should be readily available where applicable.
Nexigen’s research-material pages provide product identity and batch information so researchers can evaluate the material using documented analytical evidence.
SS-31 Batch Documentation
Nexigen Peptides provides available batch-specific analytical documentation associated with its research materials.
Depending upon the testing performed for the current SS-31 lot, documentation may include:
- Compound identity
- Lot or batch number
- Testing date
- Analytical methodology
- Reported chromatographic result
- Molecular-identity information
- Testing laboratory information
- Original analytical report
Analytical results apply only to the material and lot identified in the corresponding documentation.
How Is SS-31 Research Material Evaluated?
Different analytical techniques provide different information about a synthetic peptide research material.
High-Performance Liquid Chromatography
HPLC can be used to separate components within a peptide sample and evaluate chromatographic composition under defined analytical conditions.
A chromatographic result provides information about the sample under the specific method used.
Mass Spectrometry
Mass spectrometry can provide complementary molecular information useful for evaluating material identity.
Sequence and Structural Information
Because SS-31 contains a non-standard dimethyltyrosine residue and defined stereochemistry, researchers should ensure that chemical-identity information corresponds to the actual material represented in the applicable batch documentation.
Orthogonal Characterization
Where both chromatographic and identity-related analytical methods are available, the methods can provide complementary information.
A single purity percentage should therefore not automatically be interpreted as complete structural characterization.
Laboratory Handling
Handling and preparation requirements depend upon the experimental design, analytical methodology and laboratory protocol.
Researchers should follow validated laboratory procedures, applicable scientific literature and available lot-specific documentation when preparing or handling SS-31 research material.
Particular attention should be given to:
- Material identity
- Solution conditions
- Concentration
- Buffer composition
- Temperature
- Sample exposure conditions
- Compatibility with the analytical method
Nexigen Peptides does not provide human or veterinary preparation, dosing, injection or administration instructions.
Storage of SS-31 Research Material
Store the material according to the conditions specified in the applicable product documentation and available lot-specific analytical records.
Laboratory personnel should use appropriate procedures to minimize unnecessary exposure to moisture, light, temperature fluctuations or other environmental conditions that could affect research-material integrity.
Where validated compound-specific or batch-specific stability information is available, researchers should follow that documentation rather than generalized storage recommendations.
Current SS-31 and Elamipretide Research
SS-31/elamipretide has progressed from primarily experimental mitochondrial research into both advanced clinical investigation and an FDA-approved pharmaceutical context.
Recent scientific literature has examined the structure, mitochondrial targeting and experimental history of elamipretide, including research involving cardiolipin, mitochondrial organization and bioenergetic systems.
In September 2025, the FDA granted accelerated approval to Forzinity (elamipretide) for a defined Barth syndrome indication, with continued confirmatory research required under the accelerated approval pathway.
This history illustrates the importance of distinguishing experimental research involving SS-31 from the FDA-approved pharmaceutical product Forzinity and from the Nexigen laboratory research material listed on this page.
Nexigen does not represent its research material as an approved medicine.
Selected SS-31 Research References
First-in-Class Cardiolipin-Protective Compound and Mitochondrial Bioenergetics
This review discusses SS-31 as a Szeto-Schiller peptide and examines research involving cardiolipin interactions and mitochondrial membrane systems.
PubMed PMID: 24117165.
Elamipretide: Structure, Molecular Interactions and Research Development
A recent review summarizes the structure and research history of elamipretide/SS-31 across mitochondrial experimental systems.
PubMed PMID: 39940712.
FDA Regulatory Record for Elamipretide
The FDA granted accelerated approval to Forzinity (elamipretide) on September 19, 2025, for its specific approved indication.
SS-31 Research Peptide FAQ
What is SS-31?
SS-31 is a synthetic tetrapeptide investigated extensively in research involving mitochondrial membranes and cardiolipin-associated molecular interactions.
Is SS-31 the same as elamipretide?
Yes. SS-31 is also known as elamipretide and has also appeared in scientific literature under the development name MTP-131.
Is SS-31 a peptide?
Yes. SS-31/elamipretide is a synthetic tetrapeptide containing four amino-acid-related residues.
What is the SS-31 sequence?
The sequence is represented as:
D-Arg-2,6-dimethylTyr-Lys-Phe-NH2
What is the CAS number for SS-31?
The CAS number associated with elamipretide is:
736992-21-5
What is the molecular formula of SS-31?
The molecular formula is:
C32H49N9O5
What is the molecular weight of SS-31?
The molecular weight is approximately:
639.8 g/mol
What is cardiolipin?
Cardiolipin is a phospholipid strongly associated with the inner mitochondrial membrane. It has been an important subject of SS-31 research because scientific studies have examined interactions between SS-31 and cardiolipin-containing membrane systems.
Does Nexigen provide SS-31 batch documentation?
Available lot-specific analytical documentation may be provided for Nexigen SS-31 research material.
Researchers should verify that the documentation corresponds to the specific lot being evaluated.
Is elamipretide an FDA-approved drug?
Yes. The FDA granted accelerated approval to Forzinity (elamipretide) in September 2025 for a specific Barth syndrome indication.
The Nexigen research material should not be interpreted as the FDA-approved pharmaceutical product.
Does Nexigen provide SS-31 dosing or administration instructions?
No. Nexigen Peptides does not provide human or veterinary dosing, injection, administration or treatment instructions.
What is Nexigen SS-31 intended for?
Nexigen SS-31 is presented exclusively as a material for legitimate laboratory, analytical and scientific research.
Research Use Only
Nexigen SS-31 10 mg is supplied exclusively for legitimate laboratory, analytical and scientific research.
This material is not represented as Forzinity or as an FDA-approved pharmaceutical product and is not intended for human or veterinary use or consumption, clinical use, diagnosis, treatment, cure or prevention of disease.
Nexigen Peptides does not provide medical advice, human or veterinary dosing recommendations, injection instructions or administration guidance.
